Adlai Nortye Ltd. ANL

Annual Quarterly

FY2023 · ended Dec 31, 2023 · Revenue $5.00M · Filed May 12, 2025

Adlai Nortye Ltd. (ANL) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$52.0 million. As of Dec 31, 2024 it held $60.9 million in cash and investments and $53.6 million in total debt.

Revenue
$5.00M
Net income
$-51.87M
+52.5% vs prior year
Operating cash flow
$-51.82M
+8.5% vs prior year
Free cash flow
$-51.99M
+8.6% vs prior year
EPS
$-0.54
+78.6% vs prior year
Dividend per share
None
Shares outstanding
40.44M
Net cash
$7.35M
FY 2024
Operating margin
-1451.0%
FY 2023

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ANL (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Singapore
Headquarters
Singapore
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1944552
Former names
Adlai Nortye Ltd. (until Aug 19, 2026)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
Revenue
—
$5.0M
Operating income
-$52.9M
-$72.6M
Net income
-$51.9M
-$109.2M
Diluted EPS
-$0.54
-$2.52
Operating cash flow
-$51.8M
-$56.7M
Free cash flow
-$52.0M
-$56.9M
Total assets
$71.3M
$130.2M
Total liabilities
$45.8M
$55.1M
Stockholders' equity
$25.5M
$75.0M
Cash and investments
$60.9M
$91.5M
Total debt
$53.6M
$61.9M

Recent SEC filings

Form Description Filed Period
6-K Current report (foreign issuer) Oct 28, 2026 Oct 28, 2026
6-K Current report (foreign issuer) Oct 15, 2026 Oct 15, 2026
6-K Current report (foreign issuer) Sep 30, 2026 Sep 30, 2026
6-K Current report (foreign issuer) Sep 30, 2026 Sep 30, 2026
6-K Current report (foreign issuer) Sep 8, 2026 Sep 8, 2026
6-K Current report (foreign issuer) Aug 26, 2026 Aug 26, 2026

All 114 Adlai Nortye Ltd. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.